阿奇霉素联合头孢曲松钠对难治性肺炎支原体肺炎患儿症状缓解时间及安全性的影响OA

Objective To explore the effects of azithromycin combined with ceftriaxone sodium on symptom remission time and safety in children with refractory mycoplasma pneumoniae pneumonia.Methods A total of 116 children with refractory mycoplasma pneumoniae pneumonia received in our hospital from February 2021 to September 22 were selected as the study objects,and were randomly assigned to group A and Group B,58 cases in each group,which were treated with ceftriaxone sodium and azithromycin combined with ceftriaxone sodium,respectively.The therapeutic effect,respiratory symptoms and systemic symptoms remission time,inflammatory indicators and adverse reactions were compared between the two groups.Results The effective rate of group B was 96.55%,higher than group A 84.48%,the difference was statistically significant(P＜0.05);The time of cough,dyspnea,disappearance of pulmonary rales,mental state,appetite state,sleep quality improvement time,fever remission time and hospital stay in group B were shorter than those in group A,and the differences were statistically significant(P＜0.05);Before treatment,the levels of C-reactive protein(CRP),erythrocyte sedimentation rate(ESR)and white blood cell count(WBC)in group B were similar to those in group A,and the differences were not statistically significant(P＞0.05);After treatment,the levels of CRP,ESR and WBC in group B were lower than those in group A,and the differences were statistically significant(P＜0.05);The incidence of adverse reactions in group B was 6.90%,which was similar to 3.45%in group A,and the difference was not statistically significant(P＞0.05).Conclusion Compared with ceftriaxone sodium alone,azithromycin combined with ceftriaxone sodium in the treatment of refractory mycoplasma pneumoniae pneumonia can improve the therapeutic effect,shorten the relief time of respiratory symptoms and systemic symptoms,and reduce the level of inflammatory indicators,with good safety.